United States - English - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - zinc acetate (unii: fm5526k07a) (zinc cation - unii:13s1s8sf37) - zinc cation 25 mg - zinc acetate therapy is indicated for maintenance treatment of patients with wilson’s disease who have been initially treated with a chelating agent (see precautions: monitoring patients). zinc acetate capsules are contraindicated in patients with known hypersensitivity to any of the components of the formulation.

Philippines - English - FDA (Food And Drug Administration)

rdl pharma'l laboratory inc - hydroquinone , tretinoin - solution - 40mg/20 mcg per ml (4%/0.002% w/v)

Philippines - English - FDA (Food And Drug Administration)

rdl pharma'l laboratory inc - hydroquinone,tretinoin - solution - 20mg/125mcg per ml (2%/0.0125% w/v)

Philippines - English - FDA (Food And Drug Administration)

rdl pharmaceutical laboratory, inc. - methyl salicylate , camphor , menthol - liniment - 15.80ml/ 9.20g/ 7.50g per 100ml

European Union - English - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - precursor cell lymphoblastic leukemia-lymphoma - antineoplastic agents - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0.1%. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.2).,

European Union - English - EMA (European Medicines Agency)

janssen-cilag international n.v. - telaprevir - hepatitis c, chronic - antivirals for systemic use - incivo, in combination with peginterferon alfa and ribavirin, is indicated for the treatment of genotype-1 chronic hepatitis c in adult patients with compensated liver disease (including cirrhosis):who are treatment naïve;who have previously been treated with interferon alfa (pegylated or non-pegylated) alone or in combination with ribavirin, including relapsers, partial responders and null responders.

United States - English - NLM (National Library of Medicine)

boehringer ingelheim animal health usa inc. - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 40 [iu] in 1 ml - prozinc is contraindicated in cats sensitive to protamine zinc recombinant human insulin or any other ingredients in prozinc. prozinc is contraindicated during episodes of hypoglycemia. prozinc is contraindicated in dogs sensitive to protamine zinc recombinant human insulin or any other ingredients in prozinc. prozinc is contraindicated during episodes of hypoglycemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - sodium ascorbate, quantity: 112.5 mg (equivalent: ascorbic acid, qty 100 mg); ascorbic acid, quantity: 150 mg; zinc gluconate, quantity: 45 mg (equivalent: zinc, qty 6.5 mg) - tablet, chewable - excipient ingredients: hypromellose; magnesium stearate; maize starch; glucose monohydrate; microcrystalline cellulose; sucralose; silicon dioxide; maltodextrin; ascorbic acid; purified water; acacia; soya oil; dunaliella salina; citric acid; sucrose; mixed (low-alpha type) tocopherols concentrate; flavour - maintain/support collagen formation ; maintain/support healthy immune system function ; decrease/reduce/relieve common cold duration ; decrease/reduce/relieve the severity of common cold symptoms ; maintain/support skin health ; maintain/support wound healing

Ireland - English - HPRA (Health Products Regulatory Authority)

pharma regulatory solutions ltd - voriconazole - pdr for soln for infusion - 200 milligram - triazole derivatives - antimycotics for systemic use, triazole derivatives - voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows: treatment of invasive aspergillosis. treatment of candidaemia in non-neutropenic patients. treatment of fluconazole-resistant serious invasive candida infections (including c. krusei). treatment of serious fungal infections caused by scedosporium spp. and fusarium spp. voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections. prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

European Union - English - EMA (European Medicines Agency)

mylan pharmaceuticals limited - aripiprazole - schizophrenia; bipolar disorder - psycholeptics - aripiprazole mylan pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.aripiprazole mylan pharma is indicated for the treatment of moderate to severe manic episodes in bipolar i disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.aripiprazole mylan pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in bipolar i disorder in adolescents aged 13 years and older.